Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

The user has been using finasteride consistently for 2 years and oral minoxidil for 4 months, noticing some hair regrowth. They also take vitamin D supplements to improve hair growth.

Minoxidil and LLLT are compared for treating hair loss, with LLLT showing higher regrowth rates and fewer side effects. LLLT is less time-consuming and more suitable for those with health issues, while Minoxidil requires daily application.

DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Finasteride and minoxidil can revive hair dormant for up to 7 years, with microneedling enhancing regrowth. Users report significant hair regrowth even after long periods of baldness.

User saw hair growth after three months of using oral finasteride, microneedling, serums, and devices. Minoxidil did not work for them, and they previously had a hair transplant.

A user is using topical finasteride, keto shampoo, microneedling, and tretinoin for hair loss and is considering adding pyrilutamide. They notice some improvement at the temples and seek advice on whether to focus on cosmetic results despite daily shedding.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user started taking 2.5mg minoxidil tablets daily and reduced their finasteride dose to 0.5mg due to side effects. They are considering a hair transplant but are unsure if they should proceed now or wait after seeing the effects of the reduced finasteride dosage.

The conversation discusses verteporfin as a potential hair loss treatment and questions why more precise methods aren't used to test its effectiveness in regrowing hair. Some users believe verteporfin is promising and should receive more attention, while others are skeptical about the testing methods.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

A 27-year-old woman experiencing significant hair loss is using spironolactone, Nizoral shampoo, and betamethasone valerate. She questions the effectiveness of these treatments and whether she should seek another dermatologist.

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Betacarotene's effect on hair loss is discussed, with concerns about excessive vitamin A. The user also questions if 15mg melatonin impacts vitamin A levels.

The conversation discusses Shiseido's RepliCel Hair-01 technology for hair regeneration, which aims to stop hair loss with minimal regrowth. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.

Hair loss treatments include topical and oral minoxidil, low-level laser light therapy, and peptide serums. Bryan Johnson avoids finasteride and dutasteride due to potential side effects, focusing instead on his own protocol with these treatments.

Dutasteride may reduce bone mineral density, but there's no increased risk of osteoporosis or fractures compared to finasteride. Users suggest resistance training to counter potential bone effects.

The conversation is about hair loss treatments, specifically using dutasteride and oral minoxidil, and exploring additional vitamins and supplements like vitamin D, zinc, biotin, and omega-3 to support hair health. Users suggest getting a blood panel to identify deficiencies and emphasize the importance of protein and overall nutrition.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

A new serum claims to enhance hair regrowth by amplifying oxygen delivery, improving the effectiveness of treatments like exosomes and peptides. Users are skeptical, questioning its efficacy compared to established treatments like Minoxidil and Finasteride.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Exploring the idea of using facial hair properties for scalp regeneration in male pattern baldness, considering the potential of transferring androgen-resistant characteristics from facial hair to the scalp. Challenges include complexity, scalability, aesthetics, and safety, but the concept encourages innovative thinking beyond current treatments like Minoxidil, Finasteride, and hair transplants.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.